Status:

UNKNOWN

Epidemiological Survey on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

Lead Sponsor:

Beijing Tsinghua Chang Gung Hospital

Conditions:

Fatty Liver Disease

Eligibility:

All Genders

18-75 years

Brief Summary

To investigate the prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) among adults in China

Detailed Description

Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common chronic liver disease all over the world (1). In early 2020, a new definition of MAFLD has been proposed and is becoming increasingly widel...

Eligibility Criteria

Inclusion

  • Aged between 18 and 75, both sex;
  • Able to sign informed consent.

Exclusion

  • Pregnant women and those who are implanted with pacemakers, stents or any other metal devices.

Key Trial Info

Start Date :

June 10 2022

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2022

Estimated Enrollment :

2000 Patients enrolled

Trial Details

Trial ID

NCT05421572

Start Date

June 10 2022

End Date

December 31 2022

Last Update

June 16 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Bejing Tsinghua Chang Gung Hospital

Beijing, Bejing, China, 100034

Epidemiological Survey on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) | DecenTrialz